A mechanistic approach to antiepileptic drug interactions

Annals of Pharmacotherapy

Volumn 32, Issue 5, 1998, Pages 554-563

  Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiepileptics; Drug interactions

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ATEVIRDINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CORTICOSTEROID; DELAVIRDINE; DEXAMETHASONE; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; FELBAMATE; FELODIPINE; INOTROPIC AGENT; ITRACONAZOLE; LAMOTRIGINE; MEBENDAZOLE; METHYLPREDNISOLONE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; SAQUINAVIR; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

DRUG ACTIVITY; DRUG MECHANISM; ENZYME INDUCTION; ENZYME INHIBITION; EPILEPSY; HUMAN; MEDICAL INFORMATION; PRIORITY JOURNAL; REVIEW;

ACETIC ACIDS; AMINES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; ETHOSUXIMIDE; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; GLUCURONOSYLTRANSFERASE; HUMANS; MIXED FUNCTION OXYGENASES; NIPECOTIC ACIDS; PHENOBARBITAL; PHENYTOIN; PROPYLENE GLYCOLS; TRIAZINES; VALPROIC ACID; VIGABATRIN;

EID: 0031800865     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17332     Document Type: Review

References (93)

1. Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967;19:317-66.
2. Kutt H. Phenytoin: interactions with other drugs. Part 1. Clinical aspects. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:315-28.
3. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin. Part 1. Clin Pharmacokinet 1990;18:37-60.
4. Kutt H. Phenobarbital: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:389-400.
5. Bourgeois BFD. Primidone: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:449-57.
6. Fincham RW, Schottelius DD. Primidone: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:467-75.
7. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31: 198-214.
8. Levy RH, Wurden CJ. Carbamazepine: interaction with other drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:543-54.
9. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10.
10. Tomson T, Svensson JO, Hilton-Brown P. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit 1989;11:533-9.
11. Patsalos PN, Duncan JS, Shorvon SD. Effect of removal of individual antiepileptic drugs on antipyrine kinetics in patients taking polytherapy. Br J Clin Pharmacol 1988;26:253-9.
12. Testa B, Jenner P. Inhibitors of cytochrome P450s and their mechanism of action. Drug Metabol Rev 1981;21:1-117.
13. Shimada T, Yamazaki H, Mimura M, Inui T, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
14. Wright SA, Stevens JC. The human hepatic cytochromes 450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
15. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez F, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47: 1969-79.
16. Levy RH, Bajpai M. Phenytoin: interactions with other drugs. Part 2. Mechanistic aspects. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:329-44.
17. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24:1401-3.
18. Hargraves JA, Howald WN, Racha JK, Levy RH. Identification of enzymes responsible for the metabolism of phenobarbital (abstract). Int Soc Stud Xenobiotics Proc 1996;10:259.
19. Sadeque AJM, Korzekwa KR, Gonzalez FJ, Rettie AE. Identification of human liver cytochrome P450 isoenzymes responsible for the formation of 4-ene-valproic acid (abstract). Int Soc Stud Xenobiotics Proc 1995;8: 87.
20. Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol 1996;53:1191-2.
21. Glue P, Banfield CR, Perhach JL, Mather GC, Racha JK, Levy RH. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. Clin Pharmacokinet 1997;33:214-24.
22. Bialer M, Xiaodong S, Perucca E. Ethosuximide: absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:659-65.
23. Bachmann K, Chu CA, Greear V. In vivo evidence that ethosuximide is a substrate for cytochrome P450IIIA. Pharmacology 1992;45:121-8.
24. Levy RH. Cytochrome P450 isoenzymes and antiepileptic drug interactions. Epilepsia 1995;36(suppl 5):S8-13.
25. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
26. Hurst SI, Labroo R, Carlson SP, Mather GG, Levy RH. In vitro inhibition profile of valproic acid for cytochrome P-450 (abstract). Int Soc Stud Xenobiotics Proc 1997;12:64.
27. Bernus I, Dickinson G, Hooper WD, Eadie MJ. Inhibition of phenobarbitone N-glucosidation by valproate. Br J Clin Pharmacol 1994;38:411-6.
28. Yau MK, Adams MA, Warfin WA, Lai AA. A single dose and steady state pharmacokinetic study of lamotrigine in healthy male volunteers. Presented at the Third International Cleveland Clinic-Bethel Epilepsy Symposium on Antiepileptic Drug Pharmacology, Cleveland, OH, June 1992.
29. Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996;60:145-56.
30. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1994;28:1188-96.
31. Johannessen SI. Pharmacokinetics and interaction profile of topiramate. Review and comparison with other newer antiepileptic drugs. Epilepsia 1997;38:(suppl 1):S18-23.
32. Rosenfeld WE, Liao S, Kramer LD, Anderson GD, Palmer M, Levy RH, et al. Comparison of the steady state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:324-33.
33. Ostergaard LH, Gram L, Dam M. Tiagabine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:1057-61.
34. Rey G, Pons G, Olive G. Vigabatrin. Clin Pharmacokinet 1992;23:267-78.
35. Kenyon IE. Unplanned pregnancy in an epileptic. Br Med J 1972;1:686-7.
36. Janz D, Schmidt D. Antiepileptic drugs and failure of oral contraceptives (letter). Lancet 1974;1:1113.
37. Morselli PL, Rizzo M, Garattini S. Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann N Y Acad Sci 1971;179:88-107.
38. Lambie DG, Johnson RH, Nanda RN, Shakir RA. Therapeutic and pharmacokinetic effects of increasing phenytoin in chronic epileptics on multiple drug therapy. Lancet 1976;2:386-9.
39. Panegyres PK, Rischbieth RH. Fatal phenytoin warfarin interaction. Postgrad Med J 1991;67:98.
40. Nappi JM. Warfarin and phenytoin interaction (letter). Ann Intern Med 1979;90:852.
41. Browne TR, Szabo GK, Evans JE, Evans BA, Greenblatt DJ, Mikati MA. Carbamazepine increases phenytoin serum concentrations and reduces phenytoin clearance. Neurology 1988;38:1146-50.
42. Levy RH, Koch KM. Drug interactions with valproic acid. Drugs 1982; 24:543-56.
43. Haidukewych D, Rodin EA, Zielinski JJ. Derivation and evaluation of an equation for prediction of free phenytoin plasma concentrations in patients co-medicated with valproic acid. Ther Drug Monit 1989;11:134-9.
44. Kerrick JM, Wolff DL, Graves NM. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparison of two prediction methods. Ann Pharmacother 1995;29:470-4.
45. Dossing M, Pilsgaard H, Rasmussen B, Poulsen HE. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol 1983;25:015-22.
46. Anderson GD, Levy RH. Phenobarbital: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:371-7.
47. Bourgeois BF, Dodson WE, Ferrendeli JA. Interaction between primidone, carbamazepine and nicotinamide. Neurology 1982;32:1122-6.
48. G'erardin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacokinetics of carbamazepine in normal humans after single and repeated doses. J Pharmacokinet Biopharm 1976;5:521-35.
49. Levy RH, Lai AA. A pharmacokinetic model for drug interaction by enzyme induction and its application to carbamazepine-clonazepam. In: Johannessen SI, Morselli PL, Pippenger CE, Richens A, Schmidt D, Meinardi H, eds. Antiepileptic therapy. Advances in drug monitoring. New York: Raven Press, 1980:315-23.
50. Schaffler L, Bourgeois BF, Luders HO. Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. Epilepsia 1994;35:195-8.
51. Baldessarini RJ, Teicher MH, Cassidy JW, Stein MH. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1988;8:381-2.
52. Faigle JW, Feldmann KF. Carbamazepine: chemistry and biotransformation: In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995:499-514.
53. Gidal BE, Anderson GD, Seaton TL, Miyoshi RH, Wilensky AJ. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit 1993;15;405-9.
54. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine administration. Clin Pharmacol Ther 1991;50:10-5.
55. Rambeck B, Salke-Treumann A, May T, Boenigk HE. Valproic acid induced carbamazepine 10,11-epoxide toxicity in children and adolescents. Eur Neurol 1990;30:79-83.
56. McKee PJ, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res 1992;11:193-8.
57. Hedrick R, Williams F, Morin R, Lamb WA, Cate JC. Carbamazepine-erythromycin interaction leading to carbamazepine toxicity in epileptic children. Ther Drug Monit 1983;5:405-7.
58. Wroblewski BA, Singer WD, Whyte J. Carbamazepine-erythromycin interaction: case studies and clinical significance. JAMA 1986;255: 1165-7.
59. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993;34:161-2.
60. Dravet C, Mesdijian E, Cenraud B, Roger J. Interaction between carbamazepine and triacetyloeandomycin. Lancet 1977;1:810-1.
61. Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, De-Long GR. Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med 1995;149:99-101.
62. Bahls FH, Ozuna J, Ritchie DE. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 1991;41:740-2.
63. Hunt BA, Self TH, Lalonde RL, Bottorff MB. Calcium channel blockers as inhibitors of drug metabolism. Chest 1989;96:393-9.
64. Dam M, Christiansen J. Interaction of propoxyphene with carbamazepine (letter). Lancet 1977;2:509.
65. Kramer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol interaction: its mechanism examined by stable isotope technique. Ther Drug Monit 1986;8:387-92.
66. Scheyer RD, Mattson RH. Valproate: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:621-31.
67. Hillebrand G, Castro LA, van Scheidt W, Beukelmann D, Land W, Schmidt D. Valproate for epilepsy in renal transplant recipients receiving cyclosporine. Transplantation 1987;43:915-6.
68. Crawford P, Chadwick D, Cleland P, Tjia J, Cowie A. The lack of effect of valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33:23-9.
69. Yuen AWC. Lamotrigine: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:883-7.
70. Anderson GD, Gidal BE, Kantor E, Wilensky AJ. Lorazepam-valproic acid interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia 1994;35:221-5.
71. Lertora JJ, Rege AB, Greenspan DL, Akula S. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1994;56:272-8.
72. Baille TA, Sheffels PR. Valproic acid: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:589-604.
73. Sadeque AJM, Korzekwa KR, Gonzalez F, Rettie AE. Metabolism of valproic acid by human liver microsomes (abstract). Int Soc Stud Xenobiotics Proc 1994;6:273.
74. Wagner ML, Graves NM, Leppik IE, Remmel RP, Schumaker RC, Ward DL, et al. The effect of felbamate on valproic disposition. Clin Pharmacol Ther 1994;56:494-502.
75. Hooper WD, Franklin ME, Glue P, Banfield CR, Radwanski E, McLaughlin DB, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of β-oxidation. Epilepsia 1996;37:91-7.
76. Salke-Kellermann RA, May T, Boenigk HE. Influence of ethosuximide on valproic acid concentrations. Epilepsy Res 1997;26:345-59.
77. Bauer LA, Harris C, Wilensky AJ, Raisys VA, Levy RH. Ethosuximide kinetics: possible interaction with valproic acid. Clin Pharmacol Ther 1982;31:741-5.
78. van Wieringer A, Vrijlandt CM. Ethosuximide intoxication caused by interaction with isoniazid. Neurology 1983;33:1227-8.
79. Kucharczyk N. Felbamate: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:799-806.
80. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine 10,11-epoxide. Epilepsy Res 1992;11:147-50.
81. Pisani F, Xiao B, Fazio A, Spina E, Perucca E, Tomson T. Single dose pharmacokinetics of carbamazepine 10,11-epoxide in patients on lamotrigine monotherapy. Epilepsy Res 1994;19:245-8.
82. Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy 1992;5:73-9.
83. Dickins M, Sawyer DA, Moreley TJ, Parsons DN. Lamotrigine: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:871-5.
84. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996;31:309-24.
85. Fitton A, Goa KL. Lamotrigine. A review of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713.
86. Depot M, Powell JR, Messenheimer JA, Gloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990;48:346-55.
87. Busch JA, Radulovic LL, Bockbrader HN, Underwood BA, Sedman AJ, Chang T. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects (abstract). Pharm Res 1992;9(suppl 2):S315.
88. Levy RH, Bishop F, Streeter AJ, Trager WF, Kunze KL, Thummel KT, et al. Explanation and prediction of drug interactions with topiramate using CYP450 inhibition spectrum. Epilepsia 1995;36(suppl 4):47.
89. Ben-Menachem E. Topiramate. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:1063-70.
90. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995;36(suppl 6):S7-9.
91. 14C] tiagabine by human hepatic microsomes (abstract). Epilepsia 1995;36(suppl 3):S159.
92. Thomsen MS, Groes L, Schwietert HR, Jonkman JHG, Wemer J, Andreasen T, et al. Tiagabine: investigation of possible interaction with erythromycin during multiple dosing in healthy subjects. Presented at the 22nd International Epilepsy Congress, Dublin, Ireland, June 29-July 4, 1997.
93. Gatti G, Bartoli A, Marchiselli R, Michelucci R, Tassinari CA, Pisani F, et al. Vigabatrin induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993;36:603-6.